Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5610_Библиотеки_им_академика_М_И_Перельмана
.pdf
82 C. Unsworth et al.
https://t.me/med1917
incorporated into hydrogel contact lenses for the ocular delivery of the corticosteroid
Loteprednol Etabonate. An extended release was observed for up to 12 days in vitro,
a significant improvement compared with conventional administration. (Nasr et al.
2016) Nanoparticle suspensions have also been delivered to the eye using hollow
microneedles, targeting drug delivery across the sclera (Jiang et al. 2009).
4.5 Conclusions
Nanocarrier particles have dominated the research field for many years, but SDNs
have been highly productive as a translational platform for clinical nanomedicine.
The benefits of considering an SDN approach to achieve new clinical benefits are
varied, but clearly, SDNs do not provide all of the options that may be achievable
when using nanocarriers. As with all medicine develo pment, the clinical needs
should drive the technical solution, with patient-preference, adherence, clinician
benefits, scalability and cost being key parameters to consider. SDNs offer the
scope to address numerous administration routes and access a wide range of positive
outcomes. The reduction of large drug particles into the sub-micron range is conceptually the simplest route to the formation of drug nanoparticles, but, as can be
seen, there are numerous factors that need to be considered when optimising
manufacture, scale up and final product form.
References
Alkilani A, Mccrudden MT, Donnelly R. Transdermal drug delivery: innovative pharmaceutical
developments based on disruption of the barrier properties of the stratum corneum.
Pharmaceutics. 2015;7(4):438– 70.
Almeida H, et al. Applications of polymeric and lipid nanoparticles in ophthalmic pharmaceutical
formulations: present and future considerations. J Pharm Pharm Sci. 2014;17(3):278–93.
Alqahtani MS, et al. Advances in oral drug delivery. Front Pharmacol. 2021;12:618411.
Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update post COVID-19 vaccines. Bioeng
Transl Med. 2021;6(3):e10246.
Armenante PM, Akiti O. Sterilization processes in the pharmaceutical industry. In: Chemical
engineering in the pharmaceutical industry; drug product design, development, and modeling.
Hoboken: John Wiley & Sons; 2019. p. 311–79.
Badruddoza AM, et al. Core-shell composite hydrogels for controlled nanocrystal formation and
release of hydrophobic active pharmaceutical ingredients. Adv Healthc Mater. 2016;5(15):
1960–8.
Bakshi RP, et al. Long-acting injectable atovaquone nanomedicines for malaria prophylaxis. Nat
Commun. 2018;9(1):315.
Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antire-
troviral therapy. J Antimicrob Chemother. 2004;53(5):696–9.
Barenholz Y. Doxil (R) – the first FDA-approved nano-drug: lessons learned. J Control Release.
2012;160(2):117–34.

4 Solid Drug Nanoparticles 83
https://t.me/med1917
Bhalani DV, et al. Bioavailability enhancement techniques for poorly aqueous soluble drugs and
therapeutics. Biomedicines. 2022;10(9):2055.
Bhavna, et al. Nano-salbutamol dry powder inhalation: a new approach for treating broncho-
constrictive conditions. Eur J Pharm Biopharm. 2009;71(2):282–91.
Bobo D, et al. Nanoparticle-based medicines: a review of FDA-approved materials and clinical
trials to date. Pharm Res. 2016;33(10):2373–87.
Borges A, et al. Solid lipid nanoparticles as carriers of natural phenolic compounds. Antioxidants.
2020;9(10):998.
Borgstrom L, et al. Lung deposition of budesonide inhaled via Turbuhaler®: a comparison with
terbutaline sulphate in normal subjects. Eur Respir J. 1994;7(1):69–73.
Bosetti R, Jones SL. Cost-effectiveness of nanomedicine: estimating the real size of nano-costs.
Nanomedicine. 2019;14(11):1367–70.
Boverhof DR, et al. Comparative assessment of nanomaterial definitions and safety evaluation
considerations. Regul Toxicol Pharmacol. 2015;73(1):137–50.
Broadhead J, Gibson M. Parenteral dosage forms. In: Gibson M, editor. Pharmaceutical
preformulation and formulation: a practical guide from candidate drug selection to commercial
dosage form. Boca Raton: CRC Press; 2009.
Brunaugh AD, et al. Development and evaluation of inhalable composite niclosamide-lysozyme
particles: a broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae.
PLoS One. 2021;16(2):28.
Burgess DJ, Wright JC. An introduction to long acting injections and implants. In: Wright JC,
Burgess DJ, editors. Long acting injections and implants. Berlin: Springer-Verlag Berlin; 2012.
p. 1–9.
Chaurasiya B, Zhao YY. Dry powder for pulmonary delivery: a comprehensive review.
Pharmaceutics. 2020;13(1):31.
Chen HB, et al. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today.
2011;16(7–8):354–60.
Cheow WS, Xu R, Hadinoto K. Towards sustainability: new approaches to nano-drug preparation.
Curr Pharm Des. 2013;19(35):6229–45.
Chokshi NV, Khatri HN, Patel MM. Formulation, optimization, and characterization of rifampicin-
loaded solid lipid nanoparticles for the treatment of tuberculosis. Drug Dev Ind Pharm. 2018;44
(12):1975–89.
Daghistani N, Rey JA. Invega Trinza: the first four-times-a-year, long-acting injectable antipsy-
chotic agent. P T. 2016;41(4):222–7.
de Waard H, Frijlink HW, Hinrichs WL. Bottom-up preparation techniques for nanocrystals of
lipophilic drugs. Pharm Res. 2011;28(5):1220–3.
Debnath SK, et al. Development and evaluation of chitosan nanoparticles based dry powder
inhalation formulations of Prothionamide. PLoS One. 2018;13(1):e0190976.
Di L, Fish PV, Mano T. Bridging solubility between drug discovery and development. Drug Discov
Today. 2012;17(9–10):486–95.
Đorđević S, et al. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug
Deliv Transl Res. 2022;12(3):500–25.
Drummond DC, Zignani M, Leroux J-C. Current status of pH-sensitive liposomes in drug delivery.
Prog Lipid Res. 2000;39(5):409–60.
Elbaz NM, et al. Redispersible nanosuspensions as a plausible oral delivery system for curcumin.
Food Hydrocoll. 2021;121:107005.
EMA. ICH guideline Q3C (R6) on impurities: guideline for residual solvents. European Medicines
Agency; 2021. Available from https://www.ema.europa.eu/en/documents/regulatory-proce
dural-guideline/ich-guideline-q3c-r8-impurities-guideline-residual-solvents-step-5_en.pdf
Feng J, et al. Translational formulation of nanoparticle therapeutics from laboratory discovery to
clinical scale. J Transl Med. 2019;17:9.
Floyd AG, Jain S. Injectable emulsions and suspensions. In: Pharmaceutical dosage forms: dis-
persed systems. New York: Marcel Dekker; 1996.

84 C. Unsworth et al.
https://t.me/med1917
Fu TT, et al. Fluticasone propionate nanosuspensions for sustained nebulization delivery: an in vitro
and in vivo evaluation. Int J Pharm. 2019;572:9.
Gandhi A, Jana S, Sen KK. In-vitro release of acyclovir loaded Eudragit RLPO® nanoparticles for
sustained drug delivery. Int J Biol Macromol. 2014;67:478–82.
Garg T, Rath G, Goyal AK. Inhalable chitosan nanoparticles as antitubercular drug carriers for an
effective treatment of tuberculosis. Artif Cells Nanomed Biotechnol. 2016;44(3):997–1001.
Geiser M, Kreyling WG. Deposition and biokinetics of inhaled nanoparticles. Part Fibre Toxicol.
2010;7(1):2.
Geller DE, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of
tobramycin using PulmoSphere™ technology. J Aerosol Med Pulm Drug Deliv. 2011;24(4):
175–82.
Ghadi R, Dand N. BCS class IV drugs: highly notorious candidates for formulation development. J
Control Release. 2017;248:71–95.
Giardiello M, et al. Accelerated oral nanomedicine discovery from miniaturized screening to
clinical production exemplified by paediatric HIV nanotherapies. Nat Commun. 2016;7:10.
Gonella A, et al. Long-acting injectable formulation technologies: challenges and opportunities for
the delivery of fragile molecules. Expert Opin Drug Deliv. 2022;19(8):927–44.
Guan WH, et al. The technology for improving stability of nanosuspensions in drug delivery. J
Nanopart Res. 2022;24(1):38.
Hajba-Horváth E, et al. Sustainable stabilizer-free nanoparticle formulations of valsartan using
Eudragit® RLPO. Int J Mol Sci. 2021;22(23):13069.
Han T, Das DB. Potential of combined ultrasound and microneedles for enhanced transdermal drug
permeation: a review. Eur J Pharm Biopharm. 2015;89:312–28.
Hasanain F, et al. Gamma sterilization of pharmaceuticals—a review of the irradiation of excipients,
active pharmaceutical ingredients, and final drug product formulations. PDA J Pharm Sci
Technol. 2014;68(2):113–37.
Hobson JJ, et al. Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir
disoproxil fumarate in oils as candidate long-acting injectable depot formulations. Nanoscale
Adv. 2019a;1(11):4301–7.
Hobson JJ, et al. Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble
antiretroviral drugs within combination HIV therapies. Nat Commun. 2019b;10:10.
Hobson JJ, et al. Scalable nanoprecipitation of niclosamide andin vivodemonstration of long-acting
delivery afterintramuscular injection. Nanoscale. 2021;13:6410.
Holmes KK, et al. Major infectious diseases: key messages from disease control priorities. In: Major
infectious diseases, vol. 6. 3rd ed. Washington, DC: World Bank; 2017. p. 1–27.
Horn D, Rieger J. Organic nanoparticles in the aqueous phase – theory, experiment, and use. Angew
Chem Int Ed. 2001;40(23):4331–61.
Hu X, et al. A combined bottom-up/top-down approach to prepare a sterile injectable
nanosuspension. Int J Pharm. 2014a;472(1–2):130–9.
Hu X, et al. Biocompatible riboflavin laurate long-acting injectable nanosuspensions allowing
sterile filtration. Drug Deliv. 2014b;21(5):351–61.
Huh KM, et al. pH-sensitive polymers for drug delivery. Macromol Res. 2012;20(3):224–33.
Jermain SV, Brough C, Williams RO. Amorphous solid dispersions and nanocrystal technologies
for poorly water-soluble drug delivery – an update. Int J Pharm. 2018;535(1–2):379–92.
Jiang J, et al. Intrascleral drug delivery to the eye using hollow microneedles. Pharm Res. 2009;26
(2):395–403.
Johnson BK, Prud’homme RK. Chemical processing and micromixing in confined impinging jets.
AICHE J. 2003;49(9):2264–82.
Junyaprasert VB, Morakul B. Nanocrystals for enhancement of oral bioavailability of poorly water-
soluble drugs. Asian J Pharm Sci. 2015;10(1):13–23.
Karagiannidis PG, et al. Microfluidization of graphite and formulation of graphene-based conduc-
tive inks. ACS Nano. 2017;11(3):2742–55.

4 Solid Drug Nanoparticles 85
https://t.me/med1917
Kawashima Y, et al. Pulmonary delivery of insulin with nebulized dl-lactide/glycolide copolymer
(PLGA) nanospheres to prolong hypoglycemic effect. J Control Release. 1999;62(1):279–87.
Ke WR, et al. Spray drying lactose from organic solvent suspensions for aerosol delivery to the
lungs. Int J Pharm. 2020;591:7.
Kenyon EM, Hughes MF. 1.03 – oral exposure and absorption of toxicants*. In: McQueen CA,
editor. Comprehensive toxicology. 2nd ed. Oxford: Elsevier; 2010. p. 61–74.
Khan KU, et al. Overview of nanoparticulate strategies for solubility enhancement of poorly soluble
drugs. Life Sci. 2022;291:120301.
Kim J, De Jesus O. Medication routes of administration. Florida: StatPearls Publishing; 2022.
Koeppen BM, Stanton BA. 1 – physiology of body fluids. In: Koeppen BM, Stanton BA, editors.
Renal physiology. 5th ed. Philadelphia: Mosby; 2013. p. 1–14.
Kramer T, et al. A procedure to optimize scale-up for the primary drying phase of lyophilization. J
Pharm Sci. 2009;98(1):307–18.
Kumar L, et al. Advanced drug delivery systems for transdermal delivery of non-steroidal anti-
inflammatory drugs: a review. Curr Drug Deliv. 2018;15(8):1087–99.
Lai A, et al. Stabilising disproportionation of lipophilic ionic liquid salts in lipid-based formula-
tions. Int J Pharm. 2021;597:11.
Le TMH, et al. Preparation of drug nanoparticles by emulsion evaporation method. In: APCTP-
ASEAN workshop on advanced materials science and nanotechnology (AMSN08). Nha Trang:
Iop Publishing Ltd.; 2008.
Lee J, Choi JY, Park CH. Characteristics of polymers enabling nano-comminution of water-
insoluble drugs. Int J Pharm. 2008;355(1–2):328–36.
Lepeltier E, Bourgaux C, Couvreur P. Nanoprecipitation and the “Ouzo effect”: application to drug
delivery devices. Adv Drug Deliv Rev. 2014;71:86–97.
Li M, et al. Nanomilling of drugs for bioavailability enhancement: a holistic formulation-process
perspective. Pharmaceutics. 2016;8(2):35.
Li C, et al. Solid lipid nanoparticles with enteric coating for improving stability, palatability, and
oral bioavailability of enrofloxacin. Int J Nanomedicine. 2019;14:1619–31.
Littringer EM, et al. Spray drying of mannitol as a drug carrier-the impact of process parameters on
product properties. Dry Technol. 2012;30(1):114–24.
Liu Y, et al. Formulation of nanoparticles using mixing-induced nanoprecipitation for drug
delivery. Ind Eng Chem Res. 2020;59(9):4134–49.
Lu Y, et al. Developing nanocrystals for cancer treatment. Nanomedicine. 2015;10(16):2537–52.
Lucks S, Müller R. In: E.P. Office, editor. Medication vehicles made of solid lipid particles (solid
lipid nanospheres – sln). Jagotec AG Vectura Group Services Ltd; 1991.
Malamatari M, et al. Pharmaceutical nanocrystals: production by wet milling and applications. Drug
Discov Today. 2018;23(3):534–47.
Malhaire H, Lagarce F. Is the translational approach becoming a reality in nanomedicine? Eur J
Nanomed. 2015;7(2):79–83.
Markwalter CE, Prud’homme RK. Design of a small-scale multi-inlet vortex mixer for scalable
nanoparticle production and application to the encapsulation of biologics by inverse flash
nanoprecipitation. J Pharm Sci. 2018;107(9):2465–71.
McDonald TO, et al. Multicomponent organic nanoparticles for fluorescence studies in biological
systems. Adv Funct Mater. 2012;22(12):2469–78.
McDonald TO, et al. High-throughput nanoprecipitation of the organic antimicrobial triclosan and
enhancement of activity against Escherichia coli. J Mater Chem B. 2013;1(35):4455
McDonald TO, et al. Antiretroviral solid drug nanoparticles with enhanced oral bioavailability:
production, characterization, and in vitro-in vivo correlation. Adv Healthc Mater. 2014;3(3):
400–11.
McGuckin MB, et al. Nanocrystals as a master key to deliver hydrophobic drugs via multiple
administration routes. J Control Release. 2022;345:334–53.
Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble
compounds. Toxicol Pathol. 2008;36(1):43–8.
–65.

86 C. Unsworth et al.
https://t.me/med1917
Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspec-
tive on formulating poorly-water soluble compounds using wet media milling technology. Adv
Drug Deliv Rev. 2011;63(6):427–40.
Morris S, et al. Ex vivo transdermal delivery of 3 H-labelled atovaquone solid drug nanoparticles: a
comparison of topical intradermal injection and microneedle assisted administration Nanoscale
Advances 2023;5(23):6400–6404. https://doi.org/10.1039/D3NA00454F
Miguel RD, et al. Beyond formulation: contributions of nanotechnology for translation of antican-
cer natural products into new drugs. Pharmaceutics. 2022;14(8):28.
Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy:
rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47
(1):3–19.
Nasr FH, et al. Preparation and evaluation of contact lenses embedded with polycaprolactone-based
nanoparticles for ocular drug delivery. Biomacromolecules. 2016;17(2):485–95.
Newman SP. Drug delivery to the lungs: challenges and opportunities. Ther Deliv. 2017;8(8):
647–61.
Ohori R, Akita T, Yamashita C. Scale-up/tech transfer issues of the lyophilization cycle for
biopharmaceuticals and recently emerging technologies and approaches. Dry Technol.
2021;41:18.
Omerović N, Vranić E. Application of nanoparticles in ocular drug delivery systems. Heal Technol.
2020;10(1):61–78.
Owen A, Rannard SP. Solid drug nanoparticles: methods for production and pharmacokinetic
benefits. In: Bawa R, Audette GF, Rubinstein I, editors. Handbook of clinical nanomedicine:
nanoparticles, imaging, therapy and clinical applications. New York: Jenny Stanford Publish-
ing; 2016a. p. 211–32.
Owen A, Rannard S. Strengths, weaknesses, opportunities and challenges for long acting injectable
therapies: insights for applications in HIV therapy. Adv Drug Deliv Rev. 2016b;103:144–56.
Pandey R, et al. Poly (dl-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery
system for experimental tuberculosis. J Antimicrob Chemother. 2003;52(6):981–6.
Pandi P, et al. Amorphous solid dispersions: an update for preparation, characterization, mechanism
on bioavailability, stability, regulatory considerations and marketed products. Int J Pharm.
2020;586:119560.
Parmar PK, Wadhawan J, Bansal AK. Pharmaceutical nanocrystals: a promising approach for
improved topical drug delivery. Drug Discov Today. 2021;26(10):2329–49.
Patel D, Zode SS, Bansal AK. Formulation aspects of intravenous nanosuspensions. Int J Pharm.
2020;586:119555.
Patra CN, et al. Pharmaceutical significance of Eudragit: a review. Future J Pharm Sci. 2017;3(1):
33–45.
Pawar VK, et al. Engineered nanocrystal technology: in-vivo fate, targeting and applications in drug
delivery. J Control Release. 2014;183:51–66.
Peltonen L. Drug nanocrystals. In: Uchegbu IF, et al., editors. Fundamentals of pharmaceutical
nanoscience. New York: Springer New York; 2013. p. 277–97.
Piao H, et al. A novel solid-in-oil nanosuspension for transdermal delivery of diclofenac sodium.
Pharm Res. 2008;25(4):896–901.
Pramanik S, et al. Nanoparticle-based drug delivery system: the magic bullet for the treatment of
chronic pulmonary diseases. Mol Pharm. 2021;18(10):3671–718.
Qasim M, et al. Nanotechnology for diagnosis and treatment of infectious diseases. J Nanosci
Nanotechnol. 2014;14(10):7374 –87.
Rangaraj N, et al. Fabrication of ibrutinib nanosuspension by quality by design approach: intended
for enhanced oral bioavailability and diminished fast fed variability. AAPS PharmSciTech.
2019;20(8):18.
Ravenstijn P, et al. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month
formulation in patients with schizophrenia: a phase-1, single-dose, randomized, open-label
study. J Clin Pharmacol. 2016;56(3):330–9.

4 Solid Drug Nanoparticles 87
https://t.me/med1917
Rawal T, et al. Rifampicin loaded chitosan nanoparticle dry powder presents an improved thera-
peutic approach for alveolar tuberculosis. Colloids Surf B: Biointerfaces. 2017;154:321–30.
Rosenberg H, et al. Malignant hyperthermia: a review. Orphanet J Rare Dis. 2015;10(1):93.
Rubbens J, et al. Exploring gastric drug absorption in fasted and fed state rats. Int J Pharm.
2018;548(1):636–41.
Savage AC, et al. Improving maraviroc oral bioavailability by formation of solid drug
nanoparticles. Eur J Pharm Biopharm. 2019;138:30–6.
Schmidt LE, Dalhoff K. Food-drug interactions. Drugs. 2002;62(10):1481–502.
Schütte JK, et al. Comparison of the therapeutic effectiveness of a dantrolene sodium solution and a
novel nanocrystalline suspension of dantrolene sodium in malignant hyperthermia normal and
susceptible pigs. Eur J Anaesthesiol. 2011;28(4):256–64.
Schutz CA, et al. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine.
2013;8(3):449–67.
Shegokar R, Singh KK. Nevirapine nanosuspensions: stability, plasma compatibility and steriliza-
tion. J Pharm Investig. 2012;42(5):257–69.
Singh L, et al. The role of nanotechnology in the treatment of viral infections. Ther Adv Infect Dis.
2017;4(4):105–31.
Smith RJ. Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance
emerges? Proc R Soc B Biol Sci. 2006;273(1586):617–24.
Soares S, et al. Nanomedicine: principles, properties, and regulatory issues. Front Chem. 2018;6:15.
Soininen SK, et al. Human placental cell and tissue uptake of doxorubicin and its liposomal
formulations. Toxicol Lett. 2015;239(2):108–14.
Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends
Biotechnol. 2007;25(12):563 –70.
Surve DH, Jindal AB. Recent advances in long-acting nanoformulations for delivery of antiretro-
viral drugs. J Control Release. 2020;324:379–404.
Taghizadeh B, Jaafari MR, Zarghami N. New insight into the importance of formulation variables
on parenteral growth hormone preparations: potential effect on the injection-site pain. Front
Endocrinol. 2022;13:963336.
Taki E, et al. Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV. Expert Rev Anti-
Infect Ther. 2022;20(8):1135–47.
Tatham LM, et al. Towards a Maraviroc long-acting injectable nanoformulation. Eur J Pharm
Biopharm. 2019;138:92–8.
Tchessalov S, et al. Best practices and guidelines (2022) for scale-up and tech transfer in freeze-
drying based on case studies. Part 1: challenges during scale up and transfer. AAPS
PharmSciTech. 2022;24(1):21.
Thi TTH, et al. Lipid-based nanoparticles in the clinic and clinical trials: from cancer nanomedicine
to COVID-19 vaccines. Vaccines. 2021;9(4):359.
Trenkenschuh E, Friess W. Freeze-drying of nanoparticles: how to overcome colloidal instability by
formulation and process optimization. Eur J Pharm Biopharm. 2021;165:345–60.
Trezza C, et al. Formulation and pharmacology of long-acting cabotegravir. Curr Opin HIV AIDS.
2015;10(4):239–45.
Usach I, et al. Subcutaneous injection of drugs: literature review of factors influencing pain
sensation at the injection site. Adv Ther. 2019;36(11):2986–96.
Valenzuela P, Simon JA. Nanoparticle delivery for transdermal HRT. Nanomedicine. 2012;8:
S83–9.
Vasconcelos T, et al. Amorphous solid dispersions: rational selection of a manufacturing process.
Adv Drug Deliv Rev. 2016;100:85–101.
Verma V, Ryan KM, Padrela L. Production and isolation of pharmaceutical drug nanoparticles. Int J
Pharm. 2021;603:120708.
Vora LK, et al. Novel nanosuspension-based dissolving microneedle arrays for transdermal delivery
of a hydrophobic drug. J Interdiscip Nanomed. 2018;3(2):89–101.

88 C. Unsworth et al.
https://t.me/med1917
Wang Y, et al. The influence of nanoparticle properties on oral bioavailability of drugs. Int J
Nanomedicine. 2020;15:6295 –310.
Williams PE, Crauwels HM, Basstanie ED. Formulation and pharmacology of long-acting
rilpivirine. Curr Opin HIV AIDS. 2015;10(4):233–8.
Yadav SK, Mishra S, Mishra B. Eudragit-based nanosuspension of poorly water-soluble drug:
formulation and in vitro–in vivo evaluation. AAPS PharmSciTech. 2012;13(4):1031–44.
Yang E, Jung H-S, Chang P-S. Stimuli-responsive polymer-complexed liposome nanocarrier pro-
vides controlled release of biomolecules. Food Hydrocoll. 2022;125:107397.
Ye YH, et al. Design and evaluation of injectable niclosamide nanocrystals prepared by wet media
milling technique. Drug Dev Ind Pharm. 2015;41(9):1416–24.
Yu S, et al. Spray-freeze-dried inhalable composite microparticles containing nanoparticles of
combinational drugs for potential treatment of lung infections caused by Pseudomonas
aeruginosa. Int J Pharm. 2021;610:121160.
Yue P, et al. Nanocrystals based pulmonary inhalation delivery system: advance and challenge.
Drug Deliv. 2022;29(1):637–51.
Zahoor A, Sharma S, Khuller GK. Inhalable alginate nanoparticles as antitubercular drug carriers
against experimental tuberculosis. Int J Antimicrob Agents. 2005;26(4):298–303.
Zhang Q, Shen Z, Nagai T. Prolonged hypoglycemic effect of insulin-loaded
polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. Int J
Pharm. 2001;218(1):75–80.
Zhang HF, et al. Formation and enhanced biocidal activity of water-dispersable organic
nanoparticles. Nat Nanotechnol. 2008;3(8):506–11.
Zheng JY, Bosch HW. Sterile filtration of NanoCrystal™ drug formulations. Drug Dev Ind Pharm.
1997;23(11):1087–93.

Chapter 5
https://t.me/med1917
Lipid Nanocapsules: Latest Advances
and Applications
Juan Aparicio-Blanco and Ana Isabel Torres-Suárez
5.1 Introduction
Nanomedicines have already reached the clinical setting for the treatment of numerous diseases (Anselmo and Mitragotri 2016, 2019, 2021; Perez-Lopez et al. 2020).
Given their non-toxic, biocompatible and biodegradable nature, most of the
marketed nanomedicines are lipid-based carriers and, particularly, liposomes, as
their potential was acknowledged much earlier than any other alternative. A distinct
type of lipid-based nanomedicine with high translational potential are lipid
nanocapsules (LNCs) (Huynh et al. 2009), which have several advantages over
other lipid-based delivery systems. These advantages may be grouped into three
categories.
First, whereas most nanocarriers are manufactured using high-energy methods
wherein the required energy input is achieved by agitation of the dispersion medium
with a mechanical device, LNCs are produced by a solvent-free low-energy method,
that is, the phase inversion temperature method. Low-energy methods, with
improved formulation yiel ds, are energetically more efficient and suitable for
large-scale production because they utilize the physicochemical properties of surfactants to lower the interfacial tension and consequently lower the energy requirement for emulsification (Thomas and Lagarce 2013). Interestingly, gentle
emulsification conditions also help prevent the potential degradation of drug
substances.
J. Aparicio-Blanco · A. I. Torres-Suárez (✉)
Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense
University of Madrid, Madrid, Spain
Institute of Industrial Pharmacy, Complutense University of Madrid, Madrid, Spain
e-mail:
galaaaa@ucm.es
© The Editor(s) (if applicable) and The Author(s), under exclusive license to
Springer Nature Switzerland AG 2024
I. F. Uchegbu et al. (eds.), Fundamentals of Pharmaceutical Nanoscience,
https://doi.org/10.1007/978-3-031-59478-6_5
89

90 J. Aparicio-Blan co and A. I. Torres-Suárez
https://t.me/med1917
The phase inversion temperature met hod profits from the negligible interfacial
tension achieved when the surfactant curvature is inverted by changes in temperature
(Aparicio-Blanco et al. 2019a). Therefore, surfactants whose hydrophilic–lipophilic
balance follows a temperature-dependent pattern must be utilized, namely, non-ionic
ethoxylated surfactants. Certainly, increasing temperatures reduces the extent of
hydration of the poly(oxyethylene) moieties, which ultimately leads to inversion in
the surfactant curvature. Succinctly, all excipients (namely, aqueous and oily phases
along with non-ionic polyethoxylated surfactants) are mixed under magnetic stirring
and progressively heated over the phase inversion temperature of the system.
Subsequently, the mixture is gradually cooled down until the phase inversion
temperature was reached. At the phase inversion temperature, since the affinity for
both phases is balanced, a minimum in interfacial tension is achieved and emulsification is promoted. The final formulation is obtained following a thermal quench
below the surfactant melting point. Hence, being stabilized by the rigid surfactant
shell, nanoemulsion droplets eventually adopt the form of nanocapsules with a liquid
oily core. Although there seemed to be some controversy on the relevance of the
number of temperature cycles around the phase inversion region to prepare LNCs by
the phase inversion temperature method, we have demonstrated that neither the
average volume diameter nor the polydispersity index are significantly modified
with the number of temperature cycles (Aparicio-Blanco et al. 2019a). These results
evidence that, contrary to the traditionally postulated three temperature cycles
necessary to achieve monodisperse populations, LNCs can be obtained in a singlestep process, as a single temperature cycle around the phase inversion region is
required for their formation. These results augur very well for the industrial relevance of the phase inversion method. The simplification of the formulation procedure paves the way for the encapsulation of thermosensitive cargos, thanks to
reduced exposure to heating conditions, increases energetic yield and greatly
shortens preparation times.
Second, LNCs can be fine-tuned to be produced at highly monodisperse nominal
sizes by varying the amount of the excipients, for example, by adapting the relative
proportions of the oily phase and the non-ionic polyethoxylated surfactant. Indeed,
for low-energy methods, the formulation variables, and particularly the relative
proportion of excipients, are the most influencing parameters, as these methods do
not rely either on physical energy input or on shear forces. On the one hand, particle
size is expected to be reduced with incre asing amounts of surfactant due to the
decrease in interfacial tension. On the other hand, particle size is expected to grow
with increasing amounts of oil, as it represents the liquid core of the colloid capsules
(Lefebvre et al.
phase/surfactant mass ratio is the parameter that drives LNC formation by the phase
inversion temperature method for different oil–surfactant combinations and enables
their particle size to be predicted (Aparicio-Blanco et al. 2019a). In fact, we have
proved that particle size can be predicted with a linear univariate mathematical
model as a function of the oily phase/surfactant ratio for various oily phase–
surfactant combinations, with coefficients of determination above 0.99 in all cases.
The estimation of particle size with a univariate mathematical model is of the
). Accordingly, we have recently demonstrated that the oily
2017

5 Lipid Nanocapsules: Latest Advances and Applications 91
https://t.me/med1917
greatest importance as it will intuitively provide formulation scientists with a tool to
tailor particle size of LNCs prepared by the phase inversion temperature method.
This tailoring of particle size may be correlated to the therapeutic need, as defined by
a specific disease. Importantly, the tailoring can also be made in terms of changing
the oily phase to one that fully solubilizes the drug substance. Tailoring formulation
variables can also accommodate an increase i
switching the
concentration. This linear univariate mathematical model also accounts for the
variation of particle size from a wide variety of experimental data available in the
literature and that were originally evaluated following other parameters . Remarkably, this linear relationship does not only serve to predict particle size of
nanocapsules prepared by the P
2010),
et al.
Elgammal et al. 2015), which emphasizes the link between the governing phenomena underpinning all these formulation techniques.
A comparison among the linear plots for the different oil–surfactant combinations
revealed that there are not statistically significant differences in the Y-intercept,
which means that there exists a lower limit of particle size to be obtained with the
phase inversion temperature method, and this limit equals 10 nm, whereas the
significant differences observed in the slopes can be attributed to the difference
between the hydrophilic–lipophilic balances of the polyethoxylated surfactants and
the triglycerides utilized as oily phases. The slopes followed the pattern the closer the
hydrophilic–lipophilic balance affinity between the surfactant and the oily phase, the
lower the slope of the linear plot. Interestingly, this model can also be applied to
drug-loaded LNCs (Aparicio-Blanco et al. 2019b).
Third, the stability upon storage has been traditionally another flaw of many
nanocarriers (such as liposomes) to achieve global translational impact. In this
regard, LNCs prepared by the phase inversion temperature method have been
demonstrated to be kinetically stable in suspension against the main breakdown
mechanisms over 6 months both at room temperature and at 4 °C regardless of the
oily core/surfactant mass ratio (Aparicio-Blanco et al. 2019a). This high kinetic
stability is likely to rely on the one hand, on the presence of a solid thick surfactant
layer that noticeably precludes the passage of the liquid oily core through the
interface, and on the other hand, on the low polydispersity indexes that prevent
significant differences in Laplace pressures that ultimately account for the occurrence of Ostwald ripening.
Altogether, LNCs prepared by the phase inversion temperature method overcome
some drawbacks inherent in other colloid systems such as liposomes (namely, the
low drug payloads and the reduced stability on storage). On the one hand, thanks to
its liquid lipid core of triglyceride oils, an increase in loading of hydrophobic drugs
can be achieved. On the other hand, the formation of a solid shell of poly
(ethoxylated) surfactants that confers rigidity to the system extends the stability of
the carrier upon storage. Moreover, the linear univariate mathematical model ultimately enables monodisperse LNCs to be obtain ed “on-demand” to meet diseasedriven criteria in terms of particle size for specific therapeutic purposes.
emulsifier to one that allows LNCs to be obtained at a lower surfactant
IT m
ethod (Anton and Vandamme
also by other phase inversion methods (Morral-Ruiz et al.
but
n the maximum tolerated dose by
Roger
2009;
2014;
Соседние файлы в папке Библиотека им академика М.И. Перельмана
